AbbVie's Investigational, Pan-Genotypic Regimen Of ABT-493 And ABT-530 Shows High SVR Rates In Genotype 1 Hepatitis C Patients Who Failed Previous Therapy With Direct-Acting Antivirals

Press/Media: Press / Media

PeriodApr 15 2016 → Apr 16 2016

Media coverage

96

Media coverage

  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletBioPortfolio
    CountryUnited Kingdom
    Date4/16/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen Of ABT-493 And ABT-530 Shows High SVR Rates In Genotype 1 Hepatitis C Patients Who Failed Previous Therapy With Direct-Acting Antivirals
    Media name/outletTheStreet.com
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletPR Newswire
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletPR Newswire
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletSys-Con India
    CountryIndia
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWorldNetDaily
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletBioSpace
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletNasdaq
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletYahoo! Singapore
    CountrySingapore
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletSys-Con Media
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleENANTA PHARMACEUTICALS : AbbVie :'s Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outlet4 Traders
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1..
    Media name/outletADVFN India
    CountryIndia
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletSys-Con Belgium
    CountryBelgium
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletSys-Con Canada
    CountryCanada
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletSys-Con Australia
    CountryAustralia
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletTickerTech.com
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletBarchart
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates...
    Media name/outletStockHouse USA
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates...
    Media name/outletStockhouse Canada
    CountryCanada
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletReview Seeker
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletTutorial Finder
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletFinancial Buzz
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletIndianapolis Business Journal
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletStock Nod
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWBOC TV 16
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKCTV 5
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWAND TV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKXNet.com
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKait 8
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKPTV.com
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKTEN.com
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWVNS
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletFox 8 WVUE New Orleans
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKCEN HD
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletChannel 8 Eyewitness News
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKPLC TV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletFox 19
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWLBT
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWTRF
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKOTV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKTRE
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outlet12 News Now
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKOAM TV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletHawaii News Now
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletNewsChannel 10
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outlet35 WSEE
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWAFF
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWOWK
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWTVM
    CountryGeorgia
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKiiiTV3.com
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKHQ Right Now
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKFVS12
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWSFA
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKAUZ
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outlet3 WRCB-TV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletMyFoxTallahassee.com
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletFOX 14 TV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletCW Richmond WUPV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWTOL-TV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWMBF
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWFLX Fox 29
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKNDO KNDU
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletABC6.com
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKCBD
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKSLA
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletNews 9
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKFVE
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKTVN
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWALB 10
    CountryGeorgia
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKYTX CBS 19
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWLTZ 38
    CountryGeorgia
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKuam News 8
    CountryGuam
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKUSI.com
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKXXV-TV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWTOC TV
    CountryGeorgia
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletFox41.com
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWXTX Fox 54
    CountryGeorgia
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKSWO
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWIS-TV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWSFX-TV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletNBC12 Online
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outlet9&10 News
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletLive 5 WCSC
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWLOX
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWECT TV-6
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWDAM-TV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKLTV 7
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outlet19 Action News
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKRHD TV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWMCTV.com
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWBOY
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWave 3
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKOLD-TV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletKWES NewsWest 9
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outlet14 WFIE
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad
  • TitleAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
    Media name/outletWFMJ 21 - TV
    CountryUnited States
    Date4/15/16
    PersonsFred Poordad